

## **Supplementary information**

### **Angiogenic Properties of ‘Leukocyte- and Platelet-Rich Fibrin’**

Jessica Ratajczak<sup>1</sup>, Tim Vangansewinkel<sup>1</sup>, Pascal Gervois<sup>1</sup>, Greet Merckx<sup>1</sup>, Petra Hilkens<sup>1</sup>, Marc Quirynen<sup>2</sup>, Ivo Lambrichts<sup>1</sup>, Annelies Bronckaers<sup>1\*</sup>

<sup>1</sup> Department of Morphology, Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium


<sup>2</sup> Department of Oral Health Sciences, Katholieke Universiteit Leuven (KUL) & Periodontology, University Hospitals Leuven, Leuven, Belgium.

\* Corresponding author

**Supplementary Table S1:** Quantitative analysis of the protein array ( $n = 4$ ). Relative pixel density was measured using ImageJ in order to compare relative protein levels between L-PRF EX and L-PRF CM. Values represent the mean of the relative pixel density  $\pm$  standard deviation.

	<b>Exudate (EX)</b>	<b>Conditioned medium (CM)</b>
<b>ENA-78</b>	21.99 $\pm$ 8.73	332.31 $\pm$ 289.64
<b>GCSF</b>	9.71 $\pm$ 15.69	1.37 $\pm$ 2.11
<b>GM-CSF</b>	15.30 $\pm$ 23.38	6.43 $\pm$ 7.75
<b>GRO</b>	64.67 $\pm$ 54.58	451.43 $\pm$ 373.07
<b>GRO-<math>\alpha</math></b>	8.00 $\pm$ 8.46	122.12 $\pm$ 150.48
<b>I-309</b>	1.70 $\pm$ 2.26	0.85 $\pm$ 1.65
<b>IL-1<math>\alpha</math></b>	1.55 $\pm$ 1.95	1.50 $\pm$ 3.00
<b>IL-1<math>\beta</math></b>	9.50 $\pm$ 17.76	1.50 $\pm$ 2.48
<b>IL-2</b>	7.93 $\pm$ 14.84	0.80 $\pm$ 1.05
<b>IL-3</b>	9.68 $\pm$ 6.47	16.02 $\pm$ 26.46
<b>IL-4</b>	3.85 $\pm$ 6.06	6.18 $\pm$ 11.47
<b>IL-5</b>	1.22 $\pm$ 0.83	6.40 $\pm$ 11.15
<b>IL-6</b>	4.09 $\pm$ 5.35	20.99 $\pm$ 24.76
<b>IL-7</b>	9.13 $\pm$ 13.07	6.93 $\pm$ 7.69
<b>IL-8</b>	18.02 $\pm$ 22.69	387.32 $\pm$ 297.07
<b>IL-10</b>	10.49 $\pm$ 12.64	6.27 $\pm$ 7.40
<b>IL-12 p40/p70</b>	0.59 $\pm$ 1.19	0.85 $\pm$ 1.69
<b>IL-13</b>	0.47 $\pm$ 0.94	0.52 $\pm$ 1.04
<b>IL-15</b>	6.07 $\pm$ 9.22	0.57 $\pm$ 1.15
<b>IFN-<math>\gamma</math></b>	3.39 $\pm$ 5.89	10.69 $\pm$ 19.88
<b>MCP-1</b>	19.77 $\pm$ 12.51	181.70 $\pm$ 175.33
<b>MCP-2</b>	4.56 $\pm$ 4.66	0.81 $\pm$ 1.06
<b>MCP-3</b>	1.92 $\pm$ 2.25	2.15 $\pm$ 2.72
<b>MCSF</b>	1.92 $\pm$ 2.26	1.65 $\pm$ 2.59
<b>MDC</b>	5.65 $\pm$ 4.05	3.02 $\pm$ 4.71
<b>MIG</b>	7.42 $\pm$ 8.02	3.43 $\pm$ 3.44
<b>MIP-1<math>\beta</math></b>	14.96 $\pm$ 10.65	14.41 $\pm$ 10.50
<b>MIP-1<math>\delta</math></b>	6.25 $\pm$ 7.31	2.82 $\pm$ 4.66
<b>RANTES</b>	206.68 $\pm$ 216.36	366.24 $\pm$ 337.73
<b>SCF</b>	6.81 $\pm$ 10.40	8.39 $\pm$ 14.70
<b>SDF-1</b>	3.26 $\pm$ 5.95	19.39 $\pm$ 37.35
<b>TARC</b>	25.92 $\pm$ 23.80	18.98 $\pm$ 32.94
<b>TGF-<math>\beta</math>1</b>	3.85 $\pm$ 3.07	0.28 $\pm$ 0.33
<b>TNF-<math>\alpha</math></b>	3.72 $\pm$ 5.11	1.30 $\pm$ 1.57
<b>TNF-<math>\beta</math></b>	5.06 $\pm$ 6.25	1.53 $\pm$ 2.21
<b>EGF</b>	26.99 $\pm$ 17.17	305.92 $\pm$ 264.18
<b>IGF-I</b>	9.34 $\pm$ 11.05	2.78 $\pm$ 4.15
<b>Angiogenin</b>	60.83 $\pm$ 25.59	71.16 $\pm$ 20.17
<b>Oncostatin M</b>	4.12 $\pm$ 4.79	2.60 $\pm$ 3.72

<b>Thrombopoietin</b>	5.07 ± 8.63	16.69 ± 31.25
<b>VEGF</b>	11.28 ± 9.22	35.56 ± 66.70
<b>PDGF-BB</b>	39.50 ± 34.25	98.73 ± 119.35
<b>Leptin</b>	22.73 ± 15.31	7.96 ± 5.35
<b>BDNF</b>	5.84 ± 4.52	1.99 ± 2.41
<b>BLC</b>	1.50 ± 2.11	0.42 ± 0.84
<b>Ck β 8-1</b>	3.56 ± 4.52	1.86 ± 2.77
<b>Eotaxin</b>	5.11 ± 6.76	1.69 ± 2.72
<b>Eotaxin-2</b>	6.96 ± 6.77	4.08 ± 5.25
<b>Eotaxin-3</b>	2.76 ± 3.19	1.65 ± 3.12
<b>FGF-4</b>	0.68 ± 1.08	0.00 ± 0.00
<b>FGF-6</b>	3.01 ± 3.49	1.08 ± 2.15
<b>FGF-7</b>	4.09 ± 5.24	0.47 ± 0.95
<b>FGF-9</b>	7.85 ± 12.01	4.34 ± 6.69
<b>Flt-3 Ligand</b>	0.80 ± 0.94	0.05 ± 0.09
<b>Fractalkine</b>	0.40 ± 0.46	0.13 ± 0.27
<b>GCP-2</b>	0.75 ± 1.11	0.49 ± 0.99
<b>GDNF</b>	3.50 ± 4.54	2.04 ± 2.92
<b>HGF</b>	1.85 ± 1.87	1.15 ± 2.22
<b>IGFBP-1</b>	4.34 ± 5.36	2.79 ± 3.32
<b>IGFBP-2</b>	17.31 ± 5.04	11.55 ± 9.63
<b>IGFBP-3</b>	5.63 ± 6.51	2.68 ± 3.12
<b>IGFBP-4</b>	4.96 ± 4.67	0.71 ± 1.42
<b>IL-16</b>	8.61 ± 10.46	3.75 ± 5.60
<b>IP-10</b>	9.18 ± 6.43	3.05 ± 3.53
<b>LIF</b>	12.23 ± 14.19	3.65 ± 4.23
<b>LIGHT</b>	1.41 ± 1.75	0.54 ± 1.00
<b>MCP-4</b>	1.25 ± 1.83	0.39 ± 0.77
<b>MIF</b>	3.49 ± 5.06	3.44 ± 4.03
<b>MIP-3α</b>	4.43 ± 8.25	1.59 ± 2.53
<b>NAP-2</b>	64.93 ± 38.04	38.83 ± 13.54
<b>NT-3</b>	11.07 ± 12.84	3.41 ± 4.04
<b>NT-4</b>	2.32 ± 2.95	1.45 ± 2.14
<b>Osteopontin</b>	10.38 ± 7.66	13.70 ± 16.83
<b>Osteoprotegrin</b>	4.28 ± 3.99	1.21 ± 1.41
<b>PARC</b>	3.15 ± 3.66	1.94 ± 2.36
<b>PIGF</b>	3.22 ± 3.76	1.94 ± 2.33
<b>TGF-β2</b>	23.57 ± 9.80	8.20 ± 8.14
<b>TGF-β3</b>	1.18 ± 1.72	0.46 ± 0.92
<b>TIMP-1</b>	11.38 ± 11.84	8.55 ± 9.88
<b>TIMP-2</b>	54.15 ± 69.36	49.69 ± 28.92



**Supplementary Figure S1:** Metabolic activity of HUVEC as determined by MTT assay.

HUVEC were seeded in a 96-well plate and the next day, medium was replaced by  $\alpha$ -MEM supplemented with either 0, 1 or 10% fetal bovine serum (FBS) or EGM-2 complete medium. An MTT assay was performed at baseline levels (just before replacing the medium at 0h), and after 24h and 48h. The optical density (OD) at baseline levels was  $0.27 \pm 0.15$ . The OD levels of ‘ $\alpha$ -MEM with 0% FBS’ was not significantly reduced after 24h and 48h compared to baseline levels, indicating no significant reduction of viability. The OD of the conditions ‘ $\alpha$ -MEM 10% FBS’ or ‘EGM-2 complete medium’ was significantly increased compared to baseline after 48h ( $p < 0.001$ ). Data are presented as mean  $\pm$  SEM.  $n = 5$ , \* $= p$ -value  $< 0.001$  compared to baseline levels (0h) and compared to ‘ $\alpha$ -MEM + 0% FBS, 48h’.